Advertisement

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x100px
Organisation › Details

Byondis (Group)

Driven to improve patients’ lives, Byondis is an independent biopharmaceutical research and development company creating innovative precision medicines targeting intractable cancers and autoimmune diseases. The company is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other biopharmaceutical companies by its proprietary molecular concepts, such as its linker-drug (LD) and site-specific conjugation technologies to generate antibody-drug conjugates (ADCs). Byondis’ broad development portfolio comprises preclinical and early- and late-stage clinical programs, including the anti-HER2 ADC [vic-]trastuzumab duocarmazine (SYD985, Phase III). The company has a dedicated team of more than 350 staff including highly educated scientists and skilled technicians working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands. Byondis collaborates with global biotechnology and pharmaceutical companies and national and international academic research institutions. *

 

Period Start 2020-04-16 renamed
  Today Byondis B.V.
  Predecessor Synthon Biopharmaceuticals B.V.
Products Industry drug development
  Industry 2 antibody-drug conjugate (ADC)
Persons Person Timmers, Marco (Byondis 202008 CEO)
  Person 2 Van Heekeren, Robbert (Byondis 202009– CFO before Odyssee Mobile + Kiadis Pharma + Proxy Laboratories + Organon)
     
Region Region Nijmegen
  Country Netherlands
  Street 22 Microweg
P.O. Box 6570
  City 6503 GB Nijmegen
  Tel +31-24-679-5100
    Address record changed: 2024-01-05
     
Basic data Employees D: 101 to 500 (2020-08-19)
     
    * Document for »About Section«: Byondis B.V.. (8/19/20). "Press Release: Byondis Announces Appointment of Chief Financial Officer". Nijmegen.
     
   
Record changed: 2024-02-12

Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

More documents for Byondis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association LSE Global Village 2025 Basel 650x300px




» top